Total
0
Shares
Source: @medlabAUS Facebook
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medlab Clinical (MDC) has been awarded research and development approval from AusIndustry for a program to develop its cannabis-based pain treatment drug
  • The company was granted an “advanced and overseas finding” for the development of NanaBis as part of the Australian Federal Government’s R&D Tax Incentive program
  • Medlab says the approval will significantly extend the company’s cash runway, as well as its overall financial performance
  • The investment is said to de-risk the financial commitment associated with the last stages of its development
  • Medlab Clinical was up 3.23 per cent, trading at 16 cents at 1:50 pm AEDT

Medlab Clinical (MDC) has been awarded research and development approval from AusIndustry for a program to develop its product NanaBis.

NanaBis is Medlab’s patented lead drug candidate, developed for cancer bone pain as a viable alternative to opioids. The company said its data suggests the product may be equally effective in non-cancer neuropathic pain.

The company was granted an “advanced and overseas finding” for the development of the cannabis-based pain treatment drug by a division of the Australian Government’s Department of Industry, Science, Energy and Resources as part of the Australian Federal Government’s R&D Tax Incentive program.

Medlab says the approval will significantly extend the company’s cash runway, as well as the overall financial performance.

The total expenditure for NanaBis development in Australia and overseas for the three-year period is expected to sit at more than $26.9 million.  

Medlab CEO Dr Sean Hall said the investment de-risks the financial commitment associated with the last stages of its development.

“This outcome will directly support the company’s go-forward program for NanaBis with a 43.5 per cent cash rebate expected on the overseas expenditure in the Advanced Overseas Finding,” said Dr Hall.

“The approximate $27 million expenditure is allotted over an anticipated three years with the outcome taking 2023 into account.”

Medlab Clinical was up 3.23 per cent, trading at 16 cents at 1:50 pm AEDT.

MDC by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.
PharmAust (ASX:PAA) - Chief Scientific Officer, Richard Mollard

" PharmAust (ASX:PAA) successfully produces smaller GMP tablets

PharmAust’s (PAA) upcoming human trials have received a major boost as the company’s GMP monepantel (MPL) tablets has been produced at a smaller

" Archer Materials’ (ASX:AXE) shares rise on latest biochip development

Archer Materials (AXE) has developed sensing pathways to detect genetic information through its biochip technology.
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.